AZ, Amgen get speedy FDA review for asthma drug tezepelumabThe FDA has started a priority review of AstraZeneca and Amgen’s severe asthma antibody tezepelumab, setting a date Share XAZ, Amgen get speedy FDA review for asthma drug tezepelumabhttps://pharmaphorum.com/news/az-amgen-get-speedy-fda-review-for-severe-asthma-drug-tezepelumab/
Dermavant raises $200m to ease launch of Otezla rival tapinarofDermavant is in line to make some big payments to GlaxoSmithKline if its topical psoriasis drug tapinarof reaches Share XDermavant raises $200m to ease launch of Otezla rival tapinarofhttps://pharmaphorum.com/news/dermavant-raises-200m-to-ease-launch-of-otezla-rival-tapinarof/
Amgen pays Kyowa $400m upfront for OX40 eczema drugAmgen has made a play in a hot area of immunology R&D, paying $400 million upfront to claim Share XAmgen pays Kyowa $400m upfront for OX40 eczema drughttps://pharmaphorum.com/news/amgen-pays-kyowa-400m-upfront-for-ox40-eczema-drug/
Amgen nabs speedy approval for first-ever KRAS drug sotorasibAfter decades of mostly unsuccessful R&D, Amgen has claimed the first ever regulatory approval for a drug that Share XAmgen nabs speedy approval for first-ever KRAS drug sotorasibhttps://pharmaphorum.com/news/amgen-nabs-speedy-approval-for-first-ever-kras-drug-sotorasib/
Ex-Merck R&D chief Perlmutter takes reins at drug discovery startup EikonA new drug discovery firm, Eikon Therapeutics, has launched with former Merck & Co research chief Roger Perlmutter Share XEx-Merck R&D chief Perlmutter takes reins at drug discovery startup Eikonhttps://pharmaphorum.com/news/ex-merck-rd-chief-perlmutter-takes-reins-at-drug-discovery-startup-eikon/
BMS’ deucravacitinib psoriasis pill could launch next year after outperforming Amgen’s rivalBristol-Myers Squibb has phase 3 data from its deucravacitinib psoriasis pill, showing it outperformed Amgen’s rival Otezla in Share XBMS’ deucravacitinib psoriasis pill could launch next year after outperforming Amgen’s rivalhttps://pharmaphorum.com/news/bms-deucravacitinib-psoriasis-pill-could-launch-next-year-after-outperforming-amgens-rival/
Boehringer and MD Anderson extend KRAS cancer collaborationBoehringer Ingelheim and The University of Texas MD Anderson Cancer Center have extended and expanded a collaboration exploring Share XBoehringer and MD Anderson extend KRAS cancer collaborationhttps://pharmaphorum.com/news/boehringer-and-md-anderson-extend-kras-cancer-collaboration/
Amgen buys inflammatory diseases drug firm Rodeo for up to $721mAmgen has announced its second acquisition in the space of a month, snapping up Rodeo Therapeutics and its Share XAmgen buys inflammatory diseases drug firm Rodeo for up to $721mhttps://pharmaphorum.com/news/acquisitive-amgen-buys-inflammatory-diseases-drug-firm-rodeo-for-up-to-721m/
Amgen in $1.9bn swoop for Five Prime and its gastric cancer drugAmgen is to buy US biotech Five Prime Therapeutics for around $1.9 billion, adding a potential gastric cancer Share XAmgen in $1.9bn swoop for Five Prime and its gastric cancer drughttps://pharmaphorum.com/news/amgen-in-1-9bn-swoop-for-five-prime-and-its-gastric-cancer-drug/
